ABSTRACT
[ACEi] enalapril. Based on the compelling efficacy and primary endpoint having been met, the trial will now close early" (2).
In the paper describing the design of the trial,
McMurray et al. (3) outlined a comparison between
LCZ696, a first-in-class angiotensin receptorneprilysin inhibitor (ARNi), and enalapril. In another communication, the same authors stated that both components of the primary endpoint of the trial, cardiovascular death or hospitalization for HF, would "be analyzed separately and these additional analyses will be considered as part of the primary endpoint" (4) . 
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
In 1898, Finnish physiologist Robert Tigerstedt, who can be considered to be the first giant on whose shoulders later investigators stood, and his Swedish medical student Per Bergman, working at the Karolinska Institute in Stockholm, discovered that when saline extracts of rabbit renal cortex were injected into rabbits, a pressor response was elicited (9, 10) ( Figure 2) . They named the active component of the extract renin, which is now known to be an aspartyl protease. The next major step in the elucidation of the RAAS was taken in 1934, when Goldblatt et al. (11) demonstrated that constriction of the renal arteries of dogs caused persistent hypertension. Six years later, 2 groups, working in Argentina (12) and in the United
States (13) , demonstrated that renin catalyzed the formation of a peptide pressor substance, later named angiotensin. There were 2 forms of the latter, a largely inactive decapeptide (angiotensin I) that was cleaved by a second enzyme-a dipeptide hydrolaseangiotensin converting enzyme (ACE)-to form the active pressor substance, the octapeptide angiotensin II (Central Illustration). Subsequently, additional angiotensins, the products of further enzymatic hydrolysis, were discovered, but they are not central to this story (14) .
In addition to its action on vascular smooth muscle, angiotensin II also causes retention of sodium by enhancing reabsorption of this ion in the proximal tubule and by stimulating the release of aldosterone from the zona glomerulosa of the adrenal cortex, thereby playing a critical role in the control of extracellular fluid volume and electrolyte balance. Angiotensin II also stimulates cell proliferation, oxidative stress, and fibrosis. The RAAS acts within the bloodstream, in a classical endocrine mode, and within the kidneys and other tissues in paracrine (local) and autocrine (intracellular) modes. ACE also inactivates the vasodilator peptide, bradykinin, which contributes to its pressor action, giving the enzyme its alternate name-kininase II.
RAAS INHIBITORS.
As these important actions of ACE/kininase II became clarified, the search for inhibitors of this enzyme was begun. Ferreira made 2 important contributions. First, in 1965, he observed that the venom of Bothrops Jararaca, the Brazilian pit viper, contained an inhibitor of the kininase that degrades the vasodilator, bradykinin (15) . Subsequently, he reported that this kininase inhibitor also inhibited ACE (16) . He thus showed that the bradykinin potentiating substance and the ACEi were identical. The earliest ACEi/kininase were synthetic analogues of the active peptides in the venom and required parenteral administration. One of these, the nonapeptide, teprotide, was shown to reduce renal vasoconstriction, lower arterial pressure in hypertensive patients (17) , and improve the disordered hemodynamics in patients with HF, demonstrating the important role of activation of the RAAS in the latter (18) . Teprotide and other ACEis, in addition to raising bradykinin levels, increase the concentration of plasma and urinary prostaglandins, which are also vasodilators (19) .
These favorable effects in patients with hypertension and with HF stimulated the development of orally active ACEis, the first of which was captopril, synthesized in 1977 by Ondetti et al. (20) , a notable feat. Captopril soon became a useful antihypertensive (21) . In animal studies, it prevented ventricular remodeling in rats with myocardial infarction (22) and reduced all-cause mortality when administered long-term to patients with left ventricular dysfunction following acute myocardial infarction (23) . Other oral ACEis soon followed. Enalapril, the ACEi used as the comparator in the PARADIGM HF-trial (6) , is a prodrug that is rapidly converted into enalaprilat, its active form. The latter was shown to prolong survival in severe HF (24), whereas the prodrug improved survival in chronic HFrEF (5) . ACEis rapidly became, and remain, first-line drugs worldwide for the treatment of both hypertension and HF. ACE catalyzes the formation of ANG II, which acts on the ATIR, whose biological actions include the release of aldosterone from the adrenal cortex.
b 1 receptor blockers, ACEis, ARBs, and MRCBs block the SNS and RAAS at several levels; ACEi also blocks the degradation of bradykinin. The increasing wall stress in HFrEF activates the NPS with release of ANP and BNP, which in turn activate the NPRA, GC-A, cGMP, and PKG, and result in vasodilation, natriuresis, diuresis, and fibrosis inhibition. ANP also blocks the release of renin. NEP breaks down ANP, whereas NEPi preserves ANP by blocking NEP.
LCZ696 has 2 components-an ARB and a NEPi, which block RAAS activation while enhancing the adaptive actions of ANP. Kingston, Ontario, suggested that these atrial granules were sites of storage of a protein or polypeptide.
They then observed an inverse relation between water-electrolyte balance and atrial granularity, with hypergranularity developing in rats deprived of water and sodium, and the converse in sodium-loaded rats (33) . In their now classic paper, published in 1981, they described an experiment that is reminiscent of the one reported by Tigerstedt and Bergman (9) 83 years earlier (Figures 1 and 2 ). Their infusion of crude extracts of rat atrium caused hypotension and a more than 30-fold increase of sodium excretion, whereas urine volume rose 10-fold (34). de Bold et al. (32) named the substance responsible for these effects NEP isolated (63) ACE isolated (16) ANP discovered (34) First oral ARB (26) Patent for ARNi (97) Omapatrilat synthesized (88) First oral ACEi (20) NEPi characterized (69) PARADIGM-HF (6) 1920 1900
atrial natriuretic factor, which has subsequently been referred to as atrial natriuretic peptide (ANP). They isolated and purified ANP, determined its amino acid sequence, and developed a radioimmunoassay (35) , establishing the heart to be an endocrine organ (36) .
An endocrine function of the heart had, in fact, been suggested in 1964 (37) . trial was conducted in 25,302 hypertensive subjects.
As expected, omapatrilat was superior to lisinopril in reducing blood pressure. However, the incidence of angioedema was again significantly higher and more severe in the subjects treated with omapatrilat (2.17%) than in those receiving lisinopril (0.68%).
Among African American patients, the incidence was greater for both agents (5.53% vs. 1.62%) (93). The increased incidence of this serious, potentially lifethreatening complication was presumed to be related to the synergism between the ACE-and NEPinhibiting actions of omapatrilat on the degradation of bradykinin (94) . Omapatrilat inhibits a third enzyme, aminopeptidase P, which is also involved in the breakdown of bradykinin (95). Bradykinin is not only a vasodilator, but it also enhances prostaglandin concentrations (19) and increases vascular permeability and fluid extravasation. Hence, the question was raised as to whether omapatrilat, which initially appeared to be an attractive drug, could be a "double- 
